|
The Société Internationale d’Urologie (SIU) is pleased to support the Università di Torino in helping to disseminate its 3-minute survey to shed light on the current landscape of genetic testing and the use of PARP-inhibitors in different institutions. The answers will be acquired anonymously; the data will not be accessible to third parties and will be used only for scientific purposes.
The subject of how and when to use genetic tests and PARP-inhibitors in prostate cancer has become one of the hot topics in urology. Not all the institutions and countries are prepared for the widespread use of genetic testing (somatic and/or germline) and not all have access to PARP-inhibitors in their routine clinical practice.
|
